Navigation Links
VCU survey: US public supports genetic research, testing and government spending on research
Date:12/17/2008

g on research that advances knowledge even if there are no immediate benefits is important.

Which is more important: nature or nurture? When asked the more important influence on behavior -- the environment or genes -- a majority of respondents, 57 percent, said the environment. Similarly, most take the position that environmental factors and living practices can alter a person's likelihood for disease. Two-thirds of Americans disagree that "a person's likelihood for disease is pretty much set from birth and cannot be greatly increased or decreased by their environment and living practices."

Science and society. Fully 83 percent of Americans say that new developments in science have helped make society better. Forty-six percent say science has helped make society a lot better, while 36 percent say it has helped make society somewhat better. More than six in 10, or 61 percent, agree that scientific research is essential for improving the quality of human lives. Some ambivalence in public sentiment continues to surface when it comes to how science matches up with moral principles. A majority of the public, 53 percent, says that scientific decisions should be based primarily on an analysis of the risks and benefits involved rather than the moral and ethical issues involved, cited by 32 percent. At the same time, a majority, 56 percent, agrees that scientific research doesn't pay enough attention to the moral values of society.

Embryonic and non-embryonic stem cell research. New scientific developments have changed the landscape of stem cell research. Seven-in-10 adults favor stem cell research when it does not involve human embryos, down slightly from 75 percent just after the November 2007 announcement that human skin cells can be used to create stem cells or their near equivalents. Support for embryonic stem cell research is similar to past years: 57 percent of adults favor embryonic stem cell research, while 36 percent oppose.

'/>"/>
Contact: Anne Buckley
albuckley@vcu.edu
804-828-6052
Virginia Commonwealth University
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. New national survey says public reveres bison
2. 2008 Ullyot Public Affairs Lecture
3. Bridging public and private research on bioinformatics and proteomics
4. Indiana University research at American Public Health Association meeting
5. BIO-key(R) Announces Additional $245,000 in Third Quarter Public Safety Orders
6. Stevens strengthens Dominican Republics Early Warning System for Inundations
7. American Physical Society announces Physics, a new, free, online publication
8. FAS honors Mark D. Levine with 2008 Public Service Award
9. Healthy Minds Across America features 48 public forums on mental health research, Sept. 14
10. Springer bee expert Juergen Tautz wins prize for public communication
11. EMBO recognizes German zoologist for public communication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)... Now in its 32nd year, the CTRC-AACR San ... in breast cancer science and world leaders from industry ... , This year, more than 8,500 scientists and ... Convention Center in San Antonio from Dec. 9-13, 2009. ...
(Date:12/3/2009)... the design of the upcoming forest deal at Copenhagen in ... at the University of Leeds. , Writing today in ... 50% of the carbon credit payments to be agreed at ... should be made to forest dwellers directly, and their property ...
(Date:12/2/2009)... an increased risk of developing lung cancer in adulthood, even ... are published in Cancer Epidemiology, Biomarkers & Prevention , ... part of a special tobacco focus in the December issue. ... be diagnosed with lung cancer; more than 159,000 will die ...
Breaking Biology News(10 mins):CTRC-AACR San Antonio Breast Cancer Symposium continues to expand 2Forest deal at Copenhagen must avoid creating 'carbon refugees' 2Secondhand smoke exposure in childhood increases lung cancer risk later in life 2Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4703 1Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4703 2Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4703 3Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4703 4Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4703 5Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4703 6Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4703 7Cord Blood America Leases Las Vegas Building for Its Own Stem Cell Laboratory 51174 1Cord Blood America Leases Las Vegas Building for Its Own Stem Cell Laboratory 51174 2Cord Blood America Leases Las Vegas Building for Its Own Stem Cell Laboratory 51174 3Big Cuts in Family Budgets Usually Means Insurance Gets the Ax 51171 1Big Cuts in Family Budgets Usually Means Insurance Gets the Ax 51171 2
... (IL-2), an immune-boosting drug used experimentally in HIV therapy, ... system T cells in some HIV-positive people who respond ... of Health (NIH) Clinical Center and the National Institute ... NIH. A report describing the study, led by the ...
... heart attack and unstable angina patients placed on beta-blocker ... to a study by researchers at Washington University School ... Heart Institute in Kansas City. The study appears in ... the American Medical Association. , "In our investigation of ...
... of 72 cases of monkeypox in the United States ... fatality, even though the disease usually kills 10 percent ... patients die? New research from Saint Louis University Health ... answer. , In this month's issue of Virology, researcher ...
Other Biology News:HIV Therapy Greatly Extends Life of Key T Cells, Scientists Find 2HIV Therapy Greatly Extends Life of Key T Cells, Scientists Find 3Survival of heart patients on beta-blockers varies greatly with genetic variation 2Survival of heart patients on beta-blockers varies greatly with genetic variation 3Survival of heart patients on beta-blockers varies greatly with genetic variation 4Monkeypox mystery: New research may explain why 2003 outbreak in the US wasn't deadly 2
(Date:12/3/2009)... Inverness Medical Innovations, Inc. (NYSE: IMA ), a ... health at home through the merger of rapid diagnostics and ... on its Series B Convertible Perpetual Preferred Stock ( IMA-PB). ... stock in an amount per share equal to the quotient ...
(Date:12/2/2009)... announces that a new market research report ... Neurostimulation - A Global Market Perspective ... world neurostimulation market stands enthused by the ... resultant rise in age-related diseases such as, ...
(Date:12/2/2009)... Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today ... and dosimetry trial of Cotara® in patients with relapsed ... Cotara is a targeted monoclonal antibody linked to ... for GBM. Cotara specifically targets cells at the ...
(Date:12/2/2009)... December 2 Gamida Cell announced today,a feasibility ... of a gene therapy product which combines technology ... product may have potential to,treat inherited anemias such ... Gamida Cell is developing a series of technologies ...
Breaking Biology Technology:Reportlinker Adds Neurostimulation - A Global Market Perspective 2Reportlinker Adds Neurostimulation - A Global Market Perspective 3Reportlinker Adds Neurostimulation - A Global Market Perspective 4Reportlinker Adds Neurostimulation - A Global Market Perspective 5Reportlinker Adds Neurostimulation - A Global Market Perspective 6Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3
... Although Madison has made a deal with Georgia-based Cellnet ... not be an overnight event. Certain areas will be initially ... Square expected to be approved by the City Council in ... of Madison has taken an active role in brokering Cellnets ...
... At Third Wave Technologies, former vice president Kevin Conroy ... Puisis, who was CEO since mid-2004 and previously held other ... to Third Wave and stayed for a specific purpose," Puisis ... an upgraded, highly-skilled management team in place, that purpose has ...
... Third Wave Technologies ' compensation in a patent lawsuit ... legal fees. Stratagene is proceeding with its appeal. , ... found that Stratagene willfully infringed on two patents covering ... million. , ,Third Wave uses the technology in its ...
Other Biology Technology:Madison wireless deal goes forward with Cellnet 2
... sizes available for use with 96- or 384-well PCR ... for ease of location on 96-tube plates End ... skirt of the plate* Efficient sealing is achieved ... conjunction with screw or clip-down hot lid thermal cyclers ...
... as a wash buffer for Michels Transport Fluid ... for transportation of specimens (such as renal biopsies ... may remain in Transport Fluid for up to ... Fluid is not a fixative and is not ...
... Biotin Streptavidin-HRP Systems provide rapid, precise ... antigens in frozen or paraffin-embedded tissue, ... systems also facilitate double or triple ... performed simultaneously with primary antibodies of ...
... can be used with all ... for stacking of covered plates ... use with automated systems ... non-ridged, are available for use ...
Biology Products: